ZIOPHARM Oncology Inc. (ZIOP) and Intrexon Corp. announced Wednesday morning that they has entered into a license agreement with The University of Texas M.D. Anderson Cancer Center to develop cancer treatments.
ZIOPHARM Oncology has gapped open dramatically higher this morning and is now up 3.59 at $9.33 on the highest volume of the year. The stock has been on an upward trend since late October and has surged to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News